180 Life Sciences Corp. (NASDAQ:ATNF) Sees Significant Increase in Short Interest

by · The Markets Daily

180 Life Sciences Corp. (NASDAQ:ATNF – Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totalling 78,700 shares, an increase of 7.4% from the September 30th total of 73,300 shares. Based on an average daily volume of 1,780,000 shares, the short-interest ratio is presently 0.0 days. Currently, 16.1% of the company’s stock are sold short.

180 Life Sciences Trading Down 0.3 %

Shares of ATNF opened at $3.92 on Friday. The business’s fifty day moving average is $2.42 and its 200 day moving average is $2.05. 180 Life Sciences has a 12-month low of $1.16 and a 12-month high of $17.75.

180 Life Sciences (NASDAQ:ATNF – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported $0.01 EPS for the quarter.

180 Life Sciences Company Profile

(Get Free Report)

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.

See Also